Clinical trials: Platelet Inhibition
Pharmacodynamics
Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products
The purpose of this study is to compare the pharmacodynamic effect of clopidogrel on the platelet inhibition and the pharmacokinetic profiles of clopidogrel carboxylic acid metabolite between generic and reference clopidogrel…
- Trial name
- NCT02010632
- Testing
- Generic clopidogrel product Apolets®, Original clopidogrel product Plavix®
- Where
- Thailand
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Khon Kaen University
Ischemic Attack, Transient
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction.
- Trial name
- POINT (NCT00991029)
- Testing
- Clopidogrel
- Where
- 210 sites in United States, Australia and 8 more
- Volunteers
- 4,881 people
- Sponsor
- University of California, San Francisco
Arterial Occlusive Diseases, Coronary Artery Disease
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding.
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis
- Trial name
- TRIP-PCI (NCT02561000)
- Testing
- PZ-128
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tufts Medical Center
Diabetes Mellitus, Type 2, Coronary Artery Disease
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI
To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patients with DM who are known to have…
- Trial name
- OPTIMUS-6 (NCT03437044)
- Testing
- Ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
ST-Segment Elevation Myocardial Infarction
Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction
To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
- Trial name
- NCT02075125
- Testing
- Prasugrel 60 mg, Ticagrelor 180 mg
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Dong-A University
Systolic Heart Failure
Platelet Inhibition in Patients With Systolic Heart Failure
The investigators aim to determine if patients with systolic heart failure treated with prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.
- Trial name
- NCT01765400
- Testing
- Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Nebraska
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida